Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

Global TB Network Clinical Trials, Pontali, E., Raviglione, M. C. & Migliori, G. B., 30-Jun-2019, In : European Respiratory Review. 28, 152, 7 p., 190035.

Research output: Contribution to journalReview articleAcademicpeer-review

  • Global TB Network Clinical Trials
  • Emanuele Pontali
  • Mario C. Raviglione
  • Giovanni Battista Migliori

Over the past few decades, treatment of multidrug-resistant (MDR)/ extensively drugresistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 2024 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9-10 months.

The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.

Original languageEnglish
Article number190035
Number of pages7
JournalEuropean Respiratory Review
Issue number152
Publication statusPublished - 30-Jun-2019



Download statistics

No data available

ID: 93755901